Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 736,633 shares of RXRX, which is worth approximately $4.2 Million. The most recent transaction as insider was on Aug 15, 2023, when has been sold 16,913 shares (Class A Common Stock) at a price of $9.19 per share, resulting in proceeds of $155,430. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 737K

0.14% 3M change

10.16% 12M change

Total Value Held $4.2 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 15 2023	SELL Payment of exercise price or tax liability	$155,430 $9.19 p/Share	16,913 Reduced 1.9%	873,806 Class A Common Stock
Aug 09 2023	SELL Bona fide gift	-	10,000 Reduced 1.11%	890,719 Class A Common Stock
Aug 09 2023	BUY Conversion of derivative security	-	10,000 Added 1.1%	900,719 Class A Common Stock
Aug 02 2023	SELL Open market or private sale	$857,547 $13.19 p/Share	65,015 Reduced 6.8%	890,719 Class A Common Stock
Aug 02 2023	BUY Exercise of conversion of derivative security	$277,072 $6.94 p/Share	39,924 Added 4.01%	955,734 Class A Common Stock
Jul 20 2023	SELL Bona fide gift	-	10,000 Reduced 1.08%	915,810 Class A Common Stock
Jul 20 2023	BUY Conversion of derivative security	-	10,000 Added 1.07%	925,810 Class A Common Stock
Jul 12 2023	SELL Open market or private sale	$392,952 $12.35 p/Share	31,818 Reduced 3.36%	915,810 Class A Common Stock
Jul 12 2023	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 3.19%	947,628 Class A Common Stock
Jun 15 2023	SELL Bona fide gift	-	10,000 Reduced 1.08%	916,378 Class A Common Stock
Jun 15 2023	BUY Conversion of derivative security	-	10,000 Added 1.07%	926,378 Class A Common Stock
Jun 07 2023	SELL Open market or private sale	$510,745 $9.05 p/Share	56,436 Reduced 5.8%	916,378 Class A Common Stock
Jun 07 2023	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 3.11%	972,814 Class A Common Stock
May 15 2023	SELL Payment of exercise price or tax liability	$65,301 $5.6 p/Share	11,661 Reduced 1.22%	941,564 Class A Common Stock
May 03 2023	SELL Bona fide gift	-	10,000 Reduced 1.04%	955,048 Class A Common Stock
May 03 2023	SELL Open market or private sale	$155,773 $4.71 p/Share	33,073 Reduced 3.35%	953,225 Class A Common Stock
May 03 2023	BUY Conversion of derivative security	-	1,338 Added 0.14%	956,386 Class A Common Stock
May 03 2023	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 3.07%	986,298 Class A Common Stock
Apr 06 2023	SELL Open market or private sale	$265,600 $6.64 p/Share	40,000 Reduced 4.23%	906,710 Class A Common Stock
Apr 05 2023	SELL Open market or private sale	$86,092 $6.46 p/Share	13,327 Reduced 1.39%	946,710 Class A Common Stock
Apr 05 2023	SELL Bona fide gift	-	10,000 Reduced 1.07%	928,787 Class A Common Stock
Apr 05 2023	BUY Exercise of conversion of derivative security	$77,500 $2.48 p/Share	31,250 Added 3.15%	960,037 Class A Common Stock
Mar 13 2023	SELL Bona fide gift	-	3,000 Reduced 0.32%	938,787 Class A Common Stock
Mar 13 2023	BUY Conversion of derivative security	-	3,000 Added 0.32%	941,787 Class A Common Stock
Mar 09 2023	SELL Open market or private sale	$116,550 $7.77 p/Share	15,000 Reduced 1.57%	938,787 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account